Exenatide improves hypertension in a rat model of the metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 4, 2009, Pages 327-333

  Laugero, Kevin D ^a,b   Stonehouse, Anthony H ^a   Guss, Stacy ^a   Landry, Jannine ^a   Vu, Calvin ^a   Parkes, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; EXENDIN 4; GLUCOCORTICOID; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG IMPLANT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID STORAGE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; STEROID THERAPY; TELEMETRY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CORTICOSTERONE; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HYPERTENSION; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENTRICULAR; MALE; METABOLIC SYNDROME X; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TELEMETRY; TIME FACTORS; VENOMS;

EID: 68549090728     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0095     Document Type: Article

References (41)

1. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005;128:135-148. (Pubitemid 40380914)
2. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88. (Pubitemid 38045329)
3. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin- resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005;146:2069-2076. (Pubitemid 40396918)
4. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635. (Pubitemid 39441462)
5. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100. (Pubitemid 40616618)
6. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091. (Pubitemid 40616617)
7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) signifi cantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089. (Pubitemid 36877476)
8. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006;30:1332-1340. (Pubitemid 44306514)
9. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-1493. (Pubitemid 46871159)
10. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447. (Pubitemid 44349236)
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEJM 1998;339:229-234. (Pubitemid 28350165)
12. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007;21:253-256.
13. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing- induced dilated cardiomyopathy. Circulation 2004;110:955-961. (Pubitemid 39128621)
14. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide- 1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005;125:173-177. (Pubitemid 39593722)
15. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-1135. (Pubitemid 36667866)
16. Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006;316:852-859. (Pubitemid 43131015)
17. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996;67:63-68. (Pubitemid 26384196)
18. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52. (Pubitemid 34743464)
19. Young AA. No effect of exendin-4 on blood pressure in man. J Clin Invest [serial online]. 2002;July 4, 2002; http://www.jci.org/eletters/view/15595#sec1. Accessed July 23, 2008.
20. Edwards CM, Todd JF, Ghatei MA, Bloom SR. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci (Lond) 1998;95:719-724.
21. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-1143. (Pubitemid 29293967)
22. Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007;10:213-219. (Pubitemid 46789478)
23. Akana SF, Scribner KA, Bradbury MJ, Strack AM, Walker CD, Dallman MF. Feedback sensitivity of the rat hypothalamo-pituitary- adrenal axis and its capacity to adjust to exogenous corticosterone. Endocrinology 1992;131:585-594.
24. Bell ME, Bhatnagar S, Liang J, Soriano L, Nagy TR, Dallman MF. Voluntary sucrose ingestion, like corticosterone replacement, prevents the metabolic defi cits of adrenalectomy. Journal of Neuroendocrinology 2000;12:461-470. (Pubitemid 30223994)
25. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Mildly raised corticosterone excretion rates in patients with essential hypertension. J Hum Hypertens 1995;9:391-393.
26. Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR, Connor JM, Lever AF, Fraser R. Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identifi cation of genetic determinants of blood pressure. J Hypertens 1992;10:473-482.
27. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007;157:545-559.
28. Udelsman R, Ramp J, Gallucci WT, Gordon A, Lipford E, Norton JA, Loriaux DL, Chrousos GP. Adaptation during surgical stress. A reevaluation of the role of glucocorticoids. J Clin Invest 1986;77:1377-1381. (Pubitemid 16047162)
29. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S80-S85.
30. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG. Adrenocortical, autonomic, and infl ammatory causes of the metabolic syndrome: Nested case-control study. Circulation 2002;106:2659-2665. (Pubitemid 35364919)
31. Duclos M, Corcuff JB, Etcheverry N, Rashedi M, Tabarin A, Roger P. Abdominal obesity increases overnight cortisol excretion. J Endocrinol Invest 1999;22:465-471. (Pubitemid 29355564)
32. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603.
33. Stern JS, Hirsch J, Blair SN, Foreyt JP, Frank A, Kumanyika SK, Madans JH, Marlatt GA, St Jeor ST, Stunkard AJ. Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995;3:591-604.
34. Dallman MF, Bhatnagar S. Chronic stress and energy balance: Role of the hypothalamo-pituitary-adrenal axis. In: McEwen B, ed. Handbook of physiology, vol 7. New York: Oxford Univeristy Press; 2001:179-210.
35. Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann NY Acad Sci 1995;771:665-676.
36. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996;271(2 Pt 1):E317-E325. (Pubitemid 26301737)
37. Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 2008;16:1805-1812.
38. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. Journal of Neuroendocrinology 2003;278:45021-45026. (Pubitemid 37377262)
39. Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001;37:1-10.
40. Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 1999;41:55-64. (Pubitemid 29016046)
41. Malendowicz L, Nussdorfer G, Nowak K, Ziolkowska A, Cortorella T, Trejter M. Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 2003;12:237-241.